All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC

April 18th 2024

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

April 18th 2024

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

April 18th 2024

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer.

Fox Chase Cancer Center Opens First New Jersey Location in Voorhees

April 18th 2024

Fox Chase Cancer Center is proud to welcome patients to its newly opened office, which is located at 502 Centennial Boulevard in Voorhees, New Jersey.

Narayan Details How Nadofaragene Firadenovec Has Broken Ground as the First Gene Therapy for NMIBC

April 18th 2024

Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive bladder cancer.

CLL/SLL Therapy Initiation at Specialty Pharmacies May Increase Treatment Adherence Rates

April 18th 2024

Patients with chronic lymphocytic leukemia who initiated therapy through an integrated health-system specialty pharmacy had high therapy adherence rates.

EMA Grants Orphan Drug Designation to Annamycin in AML

April 18th 2024

The European Medicines Agency has granted orphan drug designation to annamycin for the treatment of patients with acute myeloid leukemia.

FDA Approves Lumisight and Lumicell DVS for Residual Breast Cancer Detection

April 18th 2024

The FDA has approved the optical imaging agent Lumisight and the Lumicell Direct Visualization System for use in fluorescence imaging in breast cancer.

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024

Paul G. Richardson, MD, speaks on the FDA’s decision to withdraw the approval of melflufen plus dexamethasone in multiple myeloma.

Zanubrutinib Associated With Longer Treatment Persistence, Duration, and TTD in Real-World MCL

April 17th 2024

Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.

Dr Tagawa on the Rationale for Investigating First-Line Nivolumab Plus Cisplatin in Urothelial Cancer

April 17th 2024

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the rationale for evaluating nivolumab plus cisplatin-based chemotherapy in first-line urothelial cancer.

Sinno Spotlights Key Clinical Trials Driving Targeted Approaches in Gynecologic Oncology

April 17th 2024

Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

April 17th 2024

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Personalized Dosimetry With Y-90 Glass Microspheres Shows Positive Activity in HCC

April 17th 2024

Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular carcinoma.

ASCO Congratulates 2024 Special Awards Recipients

April 17th 2024

ASCO and Conquer Cancer will honor individuals who have significantly impacted global cancer care across various domains at the 2024 ASCO Annual Meeting.

ROSALIE Trial of EO2401/Nivolumab/Bevacizumab in Recurrent Glioblastoma Concludes

April 17th 2024

The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.

FDA Grants Orphan Drug Designation to BVX001 in AML

April 17th 2024

BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024

Experts highlight clinical trial updates in muscle-invasive bladder cancer, frontline treatment options in metastatic urothelial carcinoma, and more.

B-Cell Receptor Signaling Activity Portends Inferior Outcomes in MCL

April 17th 2024

B-cell receptor signaling characteristics were associated with worse outcomes in patients with mantle cell lymphoma.

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

April 16th 2024

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma.